S1 filings / 67
#67
| id | 67 |
|---|---|
| company_id | 8502 |
| ticker | ALPX |
| filing_date | 2026-06-26 |
| filing_url | https://www.sec.gov/Archives/edgar/data/0001880995/000121390026072480/ |
| business_description | Alopexx is a clinical stage biotechnology company developing novel immune therapeutics targeting poly N-acetyl glucosamine (PNAG), a comp... |
| total_revenue | — |
| operating_loss | -$2,317,136 (FY2025) |
| cash_burn | — |
| total_assets | $923,695 (as of March 31, 2026) |
| created_at | 2026-07-11T21:14:31.431693+00:00 |
| updated_at | 2026-07-22T09:18:58.452079+00:00 |
| total_revenue_usd | — |
| operating_loss_usd | -2317136 |
| cash_burn_usd | — |
| total_assets_usd | 923695 |
| source_record_id | 1274 |
| tenant_id | 1 |